Riik: Iirimaa
keel: inglise
Allikas: HPRA (Health Products Regulatory Authority)
ISOSORBIDE MONONITRATE
PCO Manufacturing
60 Milligram
Tablet Prolonged Release
2000-04-14
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Imdur 60 mg Prolonged-Release, Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 60 mg isosorbide mononitrate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated, prolonged-release tablet. _Product imported from Greece, the UK and Portugal:_ Yellow oval, biconvex, tablet, scored on both sides and coded with ‘A’ and ‘ID’ on one side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prophylactic management of angina pectoris. Imdur is not indicated in the management of acute attacks of angina pectoris. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION DOSAGE Imdur 60 mg once daily to be taken in the morning. The dose may be increased to 120 mg daily, the whole dose to be given together in the morning. This will produce effective nitrate blood levels during the day with low blood levels at night to prevent the development of tolerance. The dose can be titrated to minimise the possibility of headache, by initiating treatment with a 30 mg dose, for the first two to four days. Whole Imdur tablets, or if needed, the divided halves, must not be chewed or crushed. They should be swallowed together with half a glass of water. Note that Imdur is not indicated for the relief of acute attacks, in the event of an acute attack, sublingual or buccal glyceryl trinitrate tablets should be used. _Children:_ The safety and efficacy of Imdur in children has not been established. _Elderly:_ No evidence of a need for routine dosage adjustment in the elderly has been found, but special care may be needed in those with increased susceptibility to hypotension or marked hepatic or renal insufficiency. An additional anti-anginal effect has been achieved when Lugege kogu dokumenti